CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate
Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.
You may also be interested in...
JAMA study found 24% of 89 topicals or transdermals labeled correctly for amounts of cannabinoid in the products; JCR study found 54% of 80 CBD oils were accurately labeled, 15% had higher levels and 31% had lower.
Businesses offering products with undisclosed drugs or labeled with violative claims and the absence of a federal regulation on lawful use of hemp ingredients in supplements are impediments to growth, says Thomas Aarts, NBJ founder currently managing director of Nutrition Business Advisors.
Recent 9th Circuit ruling upheld granting a firm preliminary injunction stopping competitor from using its trademarked brand for delta-8 THC products. Ruling generally runs counter to USPTO policy against accepting trademark registrations for hemp or cannabis products and specifically counters FDA stance delta-8 doesn’t meet definition of hemp under 2018 farm bill.